Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-cash Items (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Non-cash Items for 14 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-cash Items rose 15.45% year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Dec 2025, up 15.45%, and an annual FY2025 reading of $6.5 million, up 85.44% over the prior year.
  • Non-cash Items was $4.0 million for Q4 2025 at Enanta Pharmaceuticals, down from $6.5 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $49.2 million in Q3 2021 and bottomed at $459000.0 in Q4 2023.
  • Average Non-cash Items over 5 years is $8.0 million, with a median of $3.5 million recorded in 2024.
  • The sharpest move saw Non-cash Items plummeted 92.93% in 2021, then skyrocketed 725.43% in 2022.
  • Year by year, Non-cash Items stood at $2.4 million in 2021, then grew by 10.72% to $2.7 million in 2022, then tumbled by 82.91% to $459000.0 in 2023, then skyrocketed by 653.16% to $3.5 million in 2024, then rose by 15.45% to $4.0 million in 2025.
  • Business Quant data shows Non-cash Items for ENTA at $4.0 million in Q4 2025, $6.5 million in Q3 2025, and $3.9 million in Q2 2025.